Alfred G. Gilman

Alfred G. Gilman
Born	Alfred Goodman Gilman July 1, 1941
Birthplace	New Haven, Connecticut, U.S.
Died	December 23, 2015 Dallas, Texas, U.S.
Nationality	American
Occupation	Pharmacologist, biochemist
Known for	Discovery of G proteins and their role in cellular signal transduction
Education	MD–PhD, Case Western Reserve University (1969); BA, Yale University (1962)
Spouse(s)	Kathryn Hedlund
Children	3
Awards	Nobel Prize in Physiology or Medicine (1994), Albert Lasker Award for Basic Medical Research (1989), Louisa Gross Horwitz Prize (1989)

Alfred Goodman Gilman (July 1, 1941 – December 23, 2015) was an American pharmacologist and biochemist. His discovery of G proteins fundamentally changed how we understand cellular communication. These proteins work as critical intermediary molecules, transmitting chemical signals from a cell's surface to its interior. For this achievement, he shared the 1994 Nobel Prize in Physiology or Medicine with Martin Rodbell, who'd already shown that guanosine triphosphate (GTP) played a role in cell signaling. Gilman's contribution was different. He identified and purified the actual proteins that interacted with GTP to kick off signaling cascades, and he named them G proteins because of their interaction with guanine nucleotides.

He didn't come to science by accident. His father, Alfred Gilman, co-authored Goodman & Gilman's The Pharmacological Basis of Therapeutics, a landmark textbook that basically shaped modern pharmacology. That background mattered. Gilman spent more than four decades building a distinguished career at the University of Virginia, the University of Texas Southwestern Medical Center, and the Cancer Prevention and Research Institute of Texas. His research explained how hormones, neurotransmitters, and drugs actually work at the molecular level. The implications reached far: cancer treatment, heart disease, and beyond. He died in Dallas, Texas, on December 23, 2015, at age 74.

Early Life

Alfred Goodman Gilman was born on July 1, 1941, in New Haven, Connecticut. His household was soaked in pharmacology. His father, Alfred Gilman, was a professor of pharmacology who worked with Louis S. Goodman on that influential textbook. The younger Gilman's middle name, "Goodman," honored his father's collaborator and close friend.

Growing up this way gave him early exposure to biomedical research. His father's work on the pharmacological basis of therapeutics had already helped establish modern pharmacology as a field. That background provided intellectual stimulation and a real framework for understanding how drugs actually work. The family's deep connection to the discipline shaped young Alfred's path, though he'd eventually make discoveries that went far beyond traditional pharmacology into molecular biology and cellular biochemistry.

Education

At Yale University, Gilman earned a Bachelor of Arts in biology with a major in biochemistry in 1962. After graduating, he worked with Allan Conney at Burroughs Wellcome & Company, a pharmaceutical firm. That early industrial research paid off quickly. He published his first two technical papers.

Earl Wilbur Sutherland Jr. changed his trajectory. Sutherland was a renowned biochemist who'd win his own Nobel Prize in 1971 for discoveries about hormone action. He convinced Gilman to enroll in the combined MD–PhD program at Case Western Reserve University School of Medicine. Sutherland's influence pushed him toward signal transduction research. That decision mattered enormously. Gilman completed his MD–PhD at Case Western in 1969.

He then did postdoctoral research at the National Institutes of Health from 1969 to 1971, working in the laboratory of Marshall Nirenberg. Nirenberg was a Nobel laureate himself, having cracked the genetic code. He gave Gilman rigorous training in molecular biology and biochemistry. This NIH period was crucial. It equipped Gilman with the technical skills and conceptual framework he'd need for his signal transduction research.

Career

University of Virginia

In 1971, Gilman joined the University of Virginia School of Medicine as an assistant professor of pharmacology. By 1977, he was a full professor. His decade there was productive. It was during these years that he began the research program leading to his most significant contributions. He built directly on Martin Rodbell's work from the 1960s and 1970s, which had shown that GTP played a role in cellular signaling. Gilman's goal was different: identify and characterize the specific proteins mediating signal transduction between cell-surface receptors and intracellular effector enzymes.

Rodbell had proposed a "transducer" molecule coupling hormone receptors to intracellular enzymes like adenylyl cyclase. He'd shown that guanine nucleotides were required. But nobody had actually isolated or characterized the proteins doing the work. That's what Gilman's laboratory did. They identified, purified, and characterized these proteins, naming them G proteins for their interaction with guanine nucleotides, specifically GTP and GDP.

He used a clever genetic approach. His team employed mutant cell lines, particularly a variant of the S49 lymphoma cell line lacking functional adenylyl cyclase stimulation by hormones. By reconstituting the signaling system with purified proteins, they demonstrated that a specific GTP-binding protein acted as the intermediary. This was the first direct biochemical evidence for G proteins as distinct molecular entities.

University of Texas Southwestern Medical Center

In 1981, Gilman moved to the University of Texas Southwestern Medical Center at Dallas as chairman of the Department of Pharmacology. The department became one of the most important pharmacology programs in the country under his leadership. He continued expanding his G protein research, pushing deeper into how these proteins controlled cellular responses to external signals.

His research group made several key contributions at UT Southwestern. They characterized G protein subunit structure: alpha, beta, and gamma subunits. Here's how it works: when a hormone or neurotransmitter binds to a G protein-coupled receptor on the cell surface, the receptor activates the G protein by swapping GDP for GTP on the alpha subunit. The alpha subunit then breaks away from the beta-gamma complex. Both can interact with downstream effector proteins to pass the signal inside the cell. The alpha subunit has intrinsic GTPase activity, hydrolyzing GTP back to GDP and shutting down the signal. The G protein reassembles in its inactive form.

They discovered G proteins were a large, diverse family of signaling molecules. Different classes regulated different effector systems: adenylyl cyclase, phospholipase C, ion channels. This meant G proteins represented something universal in cell signaling. The implications for pharmacology were huge. G protein-coupled receptors turned out to be the largest family of cell-surface receptors in the human body. An estimated 30 to 50 percent of all marketed drugs worked through G protein-coupled receptor pathways.

Gilman chaired the Department of Pharmacology at UT Southwestern for nearly three decades before retiring in 2009.

Alliance for Cellular Signaling

He founded the Alliance for Cellular Signaling, an ambitious collaborative research initiative. The goal was understanding cellular signaling networks systematically and comprehensively. The project aimed to map all signaling pathways in specific cell types using experimental and computational approaches. This was one of the early efforts in systems biology. It brought together researchers from multiple institutions to tackle problems too big for any single lab.

Regeneron Pharmaceuticals

Gilman was a founder of Regeneron Pharmaceuticals. This biotechnology company grew into one of the major pharmaceutical companies in the United States. It focuses on developing medicines for serious medical conditions and was established in the late 1980s. Multiple approved therapies followed. Gilman's involvement reflected his interest in turning basic scientific discoveries into actual treatments.

Cancer Prevention and Research Institute of Texas

Upon retiring from UT Southwestern in 2009, Gilman became chief scientific officer of the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency established by Texas voters in 2007 to fund cancer research and prevention programs. He oversaw the scientific review and evaluation of research grant applications.

He resigned in 2012. A controversy emerged involving grants that had bypassed the normal peer review process. This wasn't just a quiet exit. His departure highlighted his commitment to scientific integrity and rigorous evaluation of research proposals. The controversy at CPRIT sparked broader reforms in the agency's governance and grant-making procedures.

Corporate and Advisory Roles

Starting in 2005, Gilman served on the board of directors of Eli Lilly and Company, one of the world's largest pharmaceutical companies. This role let him bring his expertise in pharmacology and molecular biology to strategic decisions about drug development and research priorities.

Goodman & Gilman's The Pharmacological Basis of Therapeutics

Like his father, Gilman served as editor of Goodman & Gilman's The Pharmacological Basis of Therapeutics. His father and Louis S. Goodman had first published it in 1941. Often called simply "Goodman & Gilman," it remained a standard reference in pharmacology and medical education for decades. Gilman's editorship kept the work scientifically rigorous and relevant through multiple editions.

Personal Life

Gilman married Kathryn Hedlund. The couple had three children. During the latter part of his life, he lived in Dallas, Texas, close to the University of Texas Southwestern Medical Center where he'd spent most of his career.

He served on the advisory council of the National Center for Science Education, which promotes science teaching in public schools, including evolution and climate science.

On December 23, 2015, Gilman died in Dallas at age 74. Major news outlets and scientific journals covered his death. The Washington Post noted his contributions as a Nobel Prize-winning scientist.

Recognition

Throughout his career, Gilman received numerous awards recognizing his contributions to biomedical science. The 1994 Nobel Prize in Physiology or Medicine was his most prominent honor, shared with Martin Rodbell, "for their discovery of G-proteins and the role of these proteins in signal transduction in cells." The Nobel Assembly at the Karolinska Institute emphasized how fundamental G proteins were to understanding cellular communication and response to external signals.

Before the Nobel Prize came other major recognitions. In 1984, he received the Canada Gairdner Foundation International Award, one of the most prestigious prizes in biomedical research. In 1989, he won both the Albert Lasker Award for Basic Medical Research, often seen as a precursor to the Nobel Prize, and the Louisa Gross Horwitz Prize from Columbia University.

He became a member of the National Academy of Sciences and the American Academy of Arts and Sciences. The American Association for Cancer Research elected him a Fellow of the AACR Academy, recognizing his contributions to cancer research and the broader biomedical sciences.

Case Western Reserve University recognized Gilman as one of its most distinguished alumni, noting his pioneering work in education and research.

Legacy

G proteins now stand as one of the twentieth century's foundational advances in cell biology and molecular pharmacology. They're central to G protein-coupled receptors (GPCRs), the largest superfamily of cell-surface receptors in the human genome. G protein signaling pathways control virtually every physiological process: vision, taste, smell, neurotransmission, immune function, cardiovascular regulation. The pharmaceutical impact is substantial. A large proportion of clinical drugs target GPCRs or G protein signaling pathway components.

Gilman's work built directly on Martin Rodbell's contributions. Rodbell had set up the conceptual framework for signal transduction involving GTP-binding proteins. He proposed the model. Gilman did something different. He provided definitive biochemical proof by purifying G proteins and showing their function in reconstituted systems. The complementary nature of their contributions earned them the joint 1994 Nobel Prize.

Beyond research, Gilman shaped scientific education through his stewardship of Goodman & Gilman's The Pharmacological Basis of Therapeutics. Generations of medical students and pharmacologists had access to a comprehensive, authoritative reference work because of him. His founding of the Alliance for Cellular Signaling was an early, influential effort to apply systems-level approaches to cell biology. It prefigured the growth of systems biology as a discipline.

His 2012 departure from CPRIT, driven by concerns about scientific integrity in grant review, showed his deep commitment to rigorous standards. His stance contributed to subsequent agency reforms. It reminded everyone why peer review matters for funding public research.

The AACR recognized his lasting contributions by naming him a Fellow of the AACR Academy. That honor is reserved for individuals making significant contributions to cancer research or the AACR's mission to prevent and cure cancer.